Evidence map›Paper›PMID 24115356›Full record

ArticleChemMedChem2013

Probing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor.

Timmy Mani, Degang Liu, Donghui Zhou, Liwei Li, William Eric Knabe, Fang Wang, Kyungsoo Oh, Samy O Meroueh

Open access · greenAbstract read
In one paragraph

Article in ChemMedChem, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. A Chemoselective Polarity-Mismatched Photocatalytic C(spAngewandte Chemie (International ed. in English) · 2023
    Article
  4. Article
  5. Review
  6. Unconventional Secondary Structure Mimics: Ladder-Rungs.Angewandte Chemie (International ed. in English) · 2020
    Article
  7. Therapeutics targeting the fibrinolytic system.Experimental & molecular medicine · 2020
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Timmy ManiDepartment of Biochemistry & Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202 (USA).
Degang Liu
Donghui Zhou
Liwei Li
William Eric Knabe
Fang Wang
Kyungsoo Oh
Samy O Meroueh
Indiana University School of MedicineIndiana University – Purdue University Indianapolis · US

Funding

Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI Jun Wan · 1999 to 2026
$59.3M
Small-molecule Inhibition of the Interactions of the Urokinase Receptor: A TargeR01CA135380 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI MEROUEH, SAMY · 2009 to 2012
$1.0M
NCI NIH HHS CA135380NCI NIH HHS P30 CA082709NCI NIH HHS R01 CA135380
6 · The paper itself

Abstract

The urokinase receptor (uPAR) is a cell-surface protein that is part of an intricate web of transient and tight protein interactions that promote cancer cell invasion and metastasis. Here, we evaluate the binding and biological activity of a new class of pyrrolidinone and piperidinone compounds, along with derivatives of previously-identified pyrazole and propylamine compounds. Competition assays revealed that the compounds displace a fluorescently labeled peptide (AE147-FAM) with inhibition constant (Ki ) values ranging from 6 to 63 μM. Structure-based computational pharmacophore analysis followed by extensive explicit-solvent molecular dynamics (MD) simulations and free energy calculations suggested the pyrazole-based and piperidinone-based compounds adopt different binding modes, despite their similar two-dimensional structures. In cells, pyrazole-based compounds showed significant inhibition of breast adenocarcinoma (MDA-MB-231) and pancreatic ductal adenocarcinoma (PDAC) cell proliferation, but piperidinone-containing compounds exhibited no cytotoxicity even at concentrations of 100 μM. One pyrazole-based compound impaired MDA-MB-231 invasion, adhesion, and migration in a concentration-dependent manner, while the piperidinone inhibited only invasion. The pyrazole derivative inhibited matrix metalloprotease-9 (gelatinase) activity in a concentration-dependent manner, while the piperidinone showed no effect suggesting different mechanisms for inhibition of cell invasion. Signaling studies further highlighted these differences, showing that pyrazole compounds completely inhibited ERK phosphorylation and impaired HIF1α and NF-κB signaling, while pyrrolidinones and piperidinones had no effect. Annexin V staining suggested that the effect of the pyrazole-based compound on proliferation was due to cell killing through an apoptotic mechanism. The compounds identified represent valuable leads in the design of further derivatives with higher affinities and potential probes to unravel the protein-protein interactions of uPAR.

Indexed as

ApoptosisBinding SitesCell AdhesionCell Line, TumorCell MovementHumansMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Molecular Docking SimulationPiperidinesProtein BindingProtein Structure, TertiaryPyrrolidinonesQuantitative Structure-Activity RelationshipReceptors, Urokinase Plasminogen ActivatorSignal TransductionMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3PiperidinesPyrrolidinonesReceptors, Urokinase Plasminogen Activatorcancerinhibitorsinvasionmetastasisprotein-protein interactionsmall moleculesuPARurokinaseurokinase receptors

Identifiers

PMID24115356
PMCPMC4058332
OpenAlexW2118659300

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.